Melatonin

褪黑素

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameMelatonin
Drug Alias Name松果腺素抑黑素退黑激素美拉酮宁褪黑色素 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMelatonin receptor agonists
TargetsMelatonin receptor
Therapy Area/IndicationsDiabetic peripheral neuropathyCoronavirus Disease 2019 (COVID-19)Oral Squamous Cell Carcinoma +[110] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaSleep Initiation and Maintenance Disorders
Original Approved Country/TerritoryEU
Original Approved Date2007/06/29
Country/TerritoryCanadaUnited StatesSweden +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNobelpharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChildren'S National Research InstituteWoolcock Institute Of Medical ResearchAl-Hadba university +[34] 
Inactive CompaniesNeurim Pharmaceuticals LtdDana-Farber Cancer InstitutePontificia Universidade Católica Do Rio Grande Do Sul +[49] 
Active IndicationsDiabetic peripheral neuropathyPreoperative AnxietyIschemic Stroke +[47] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Oral Squamous Cell CarcinomaSolid tumours +[63] 

Other Information

ATC CodeN05CH01
Related LinksWikipediaDrugBankKEGG